Gocovri (amantadine) has been approved by the U.S. Food and Drug Administration (FDA) as an add-on therapy for off episodes in people with Parkinson’s disease. Adamas Pharmaceuticals, which developed the therapy, announced its approval in the U.S. for Parkinson’s patients currently taking levodopa and/or carbidopa. Off…
News
Eisai Korea has launched Equfina (safinamide) in South Korea as an add-on therapy to levodopa for people with Parkinson’s disease who are experiencing “off” episodes. Equfina was approved in South Korea last year and this represents the medication’s first launch in Asia outside of Japan. Marketed as Xadago…
Brain Neurotherapy Bio (BNB) has joined with Asklepios BioPharmaceutical (AskBio), a merger aiming to expand a gene therapy program for progressive neurodegenerative diseases such as Parkinson’s and multiple system atrophy (MSA), a form of atypical parkinsonism. “I’m pleased to welcome the Brain Neurotherapy Bio team to AskBio,” Sheila…
New guidelines published by The British Psychological Society highlight the lack of mental health research and services for people living with Parkinson’s disease and other neurodegenerative conditions, and offers evidence-based recommendations for health professionals to help better serve patients. “We hope that our guidelines will add to…
Scientists have found that the Hoffmann reflex — a test often used to evaluate reflexes in the upper extremities — can be used as a biomarker to assess the correct placement of electrodes during deep brain stimulation (DBS) surgery in patients with advanced Parkinson’s disease. This reflex test,…
A survey done in Germany showed that a majority of people with Parkinson’s disease were interested in exploring medical cannabis as a treatment option, with those already using it reporting positive effects. Notably, most non-users indicated that a lack of knowledge, and the fear of side effects, had stopped…
Manus Neurodynamica, a medical technology company, has raised £1.2 million ($1.6 million) to launch NeuroMotor, a digital pen with a patented sensor technology that can help diagnose patients with Parkinson’s disease and other movement disorders. This financing round will allow the NeuroMotor Pen to be launched in…
Microba has partnered with researchers at the University of Queensland’s (UQ) Faculty of Medicine to study gut bacteria of people with Parkinson’s disease, with a goal of discovering and developing new biomarkers and therapies for this neurodegenerative disorder. A first clinical trial is planned for this year at sites…
While scientists continue to shed light on a connection between gut bacteria and Parkinson’s disease, one study has found that gut fungi appear not to contribute to the neurodegenerative disorder. This result might serve as a useful warning against investing in potentially futile anti-fungal treatments for people with…
The more anxiety a person feels early in the course of Parkinson’s disease, the less likely that person will stay physically active, which correlates with cognitive impairment. The study with that finding, “Physical activity as a mediator of anxiety and cognitive functioning in Parkinson’s disease,” was…
Recent Posts
- New trial data show early biological signals for Parkinson’s therapy
- Taking time for self-care is crucial as a caregiver
- Early trial data suggest GT-02287 may ease Parkinson’s symptoms
- The new year is a perfect time to reflect on unexpected gifts
- Webcams, AI track Parkinson’s progression using eye movement